- Published on
KembaraXtra-Medicine: Achilles Tendon Rupture
Achilles tendon rupture is a disruption of the continuity of the Achilles tendon, most commonly occurring after an eccentric loading event when the ankle is plantarflexed or when plantarflexion is forced against resistance. It is often an acute sports-related injury and can be missed initially, sometimes being mistaken for an ankle sprain. Relevant ICD-10-CM codes include S86.011 (right), S86.012 (left), M66.871 (nontraumatic right), M66.872 (nontraumatic left), and S86.0 (unspecified injury of Achilles tendon).
In the general population, Achilles tendon ruptures occur at an estimated rate of 18 per 100,000 people per year and are the most common large tendon rupture, accounting for approximately 20% to 35% of major tendon injuries. They most often occur in adults aged 30 to 55 years, with peak incidence in males aged 30 to 40 years, particularly those who participate in recreational athletics.
Risk is highest in people involved in “stop-and-go” sports such as basketball, tennis, and soccer, especially when there is a sudden increase in training intensity or duration. Additional risk factors include preexisting Achilles tendinopathy, advancing age, male sex, poor running mechanics, and a sedentary baseline followed by abrupt strenuous activity. Certain medications and substances are also associated with rupture risk, most notably fluoroquinolone antibiotics, where rupture tends to occur within the first 90 days, and steroid exposure, including prescribed corticosteroids and illicit anabolic steroid use.
The classic presentation is a middle-aged recreational athlete who feels a sudden “pop” in the posterior ankle or calf during pivoting, sprinting, jumping, or rapid deceleration, followed by acute pain and difficulty continuing activity. Pain may be severe, but some patients present primarily with weakness rather than pain and may still be able to walk. On examination, there may be swelling, bruising, and tenderness, and a palpable gap is often appreciated in the distal third of the tendon, typically 2 to 6 cm proximal to the calcaneal insertion. Patients may have an antalgic gait and are often unable to perform a single-leg heel raise due to loss of plantarflexion strength. When the patient lies prone with the feet hanging off the table, the injured side may rest in a more dorsiflexed position than the uninjured side. The Thompson test (calf squeeze test) is highly useful: squeezing the calf fails to produce normal plantarflexion when the tendon is ruptured. The Matles test (knee flexion test) provides additional support, with the injured foot falling into a more dorsiflexed or neutral position when the knees are flexed to 90 degrees.
Mechanistically, rupture is usually due to indirect trauma and reflects a combination of mechanical overload, relative hypovascularity in the classic “watershed zone” 2–6 cm above the insertion, and poor tendon tissue quality. Chronic tendinosis (degenerative change from repetitive microtears) and tendinitis can weaken the tendon, making it more susceptible to rupture during abrupt loading.
The differential diagnosis includes Achilles tendinopathy, retrocalcaneal bursitis, ankle sprain, calcaneal avulsion fracture, partial gastrocnemius tear, plantaris rupture, os trigonum syndrome, and calcaneal apophysitis. Diagnosis is largely clinical when history and exam findings are classic, but imaging can help in unclear cases or when partial tears are suspected.
Ultrasound is often used at the bedside and can identify tendon discontinuity, tendinopathy, and hematoma, making it a practical first-line study in many settings. MRI provides the greatest anatomic detail and is particularly helpful for confirming partial tears, defining the extent of injury, and assessing associated tendinopathy; a complete rupture typically shows fiber discontinuity and fluid signal at the tear site.
Initial management includes RICE (rest, ice, compression, elevation), along with analgesia such as acetaminophen or NSAIDs as appropriate. The ankle should be immobilized in a posterior slab splint with the foot in resting equinus (plantarflexion) to reduce tension on the tendon. Definitive treatment may be nonoperative or operative, and modern care increasingly uses accelerated functional rehabilitation protocols rather than prolonged casting alone.
Nonoperative treatment traditionally involved immobilization for 8 to 12 weeks, but newer accelerated protocols typically begin with about 2 weeks of immobilization, followed by progressive weight bearing in a walking boot with heel wedges to limit dorsiflexion, plus early supervised physical therapy emphasizing gradual range of motion and strengthening. These protocols have improved outcomes compared with older prolonged immobilization approaches.
Surgical repair is considered especially for acute complete ruptures, often aiming for repair within 4 weeks, and ideally within 7 to 14 days, to optimize healing and tendon length restoration. Techniques include open repair and percutaneous or minimally invasive approaches. Percutaneous repair may reduce operative time and deep infection risk but carries a higher risk of sural nerve injury. Postoperative care similarly relies on structured rehabilitation with early controlled motion and progressive strengthening.
Orthopedic referral is recommended for suspected acute or complete ruptures, as early evaluation helps guide operative versus nonoperative management and facilitates timely rehabilitation planning. Clinically important pearls include remembering that some patients may have minimal pain and may still walk, so careful palpation for a defect and performance of the Thompson test are crucial. Although surgery can reduce rerupture rates, it has higher complication risks, and randomized trials show that with modern functional rehabilitation, nonoperative treatment can achieve outcomes comparable to surgery at 12 months. Platelet-rich plasma (PRP), despite common use, has not shown benefit over placebo in several studies for acute rupture.
Prevention focuses on addressing modifiable risk factors, including maintaining conditioning, using proper training progression, continuing eccentric and concentric calf strengthening (especially after prior tendinopathy or rupture), and reducing training intensity during fluoroquinolone or anabolic steroid exposure.
- Published on
KembaraXtra-Medicine: Acetaminophen Poisoning
Acetaminophen (APAP) poisoning occurs when excessive amounts of acetaminophen are ingested, overwhelming normal hepatic metabolic pathways and leading to acute liver injury. If untreated, toxicity can progress to hepatic necrosis, liver failure, and death. Early symptoms are often nonspecific and include nausea, vomiting, diaphoresis, malaise, and abdominal discomfort, while later manifestations include jaundice, coagulopathy, hepatic encephalopathy, and multiorgan failure. Acetaminophen is also known as paracetamol, and poisoning is classified under ICD-10-CM codes T39.1 (accidental poisoning) and X60 (intentional self-poisoning).
Acetaminophen is among the most widely used antipyretic and analgesic medications worldwide and is present in over 100 prescription and over-the-counter combination products, including many cold, flu, and opioid formulations. In the United States alone, more than 100,000 potentially toxic ingestions are reported each year, making acetaminophen the most common pharmaceutical exposure reported to Poison Control Centers. It is the leading cause of acute liver failure and liver transplantation nationally. Nearly half of exposures occur in children younger than 6 years, often due to dosing errors. Individuals with chronic alcohol use disorder, malnutrition, chronic liver disease, or concurrent use of hepatotoxic drugs are at increased risk for severe toxicity.
The clinical course of acetaminophen poisoning typically follows four stages. During Stage I (0–24 hours), patients may be asymptomatic or experience nonspecific symptoms such as nausea, vomiting, anorexia, and lethargy, with laboratory studies often normal early on. Stage II (24–72 hours) marks the onset of hepatic injury, characterized by right upper quadrant abdominal pain, rising AST and ALT levels, and early abnormalities in coagulation or renal function. Stage III (72–96 hours) represents the period of maximal hepatotoxicity, with findings that may include hepatic encephalopathy, jaundice, coagulopathy, hypoglycemia, renal failure, metabolic acidosis, and death from multiorgan failure. Patients who survive this phase enter Stage IV (4 days to 2 weeks), during which hepatic regeneration occurs and clinical recovery is usually complete.
Acetaminophen toxicity results from the accumulation of N-acetyl-p-benzoquinone imine (NAPQI), a toxic metabolite normally detoxified by glutathione. When excessive acetaminophen is ingested, glutathione stores are depleted, allowing NAPQI to cause hepatocellular damage. The recommended maximum daily dose is 3-4 g in adults and 90 mg/kg in children. A single ingestion of ≥7.5 g in adults or ≥150 mg/kg in children is considered potentially toxic. Massive ingestions, often defined as >30–50 g, can produce early metabolic acidosis, altered mental status, and rapid progression to liver failure.
Diagnosis is based on history, timing of ingestion, and laboratory evaluation. A serum acetaminophen concentration obtained 4 hours or more after ingestion is plotted on the Rumack-Matthew nomogram to estimate the risk of hepatotoxicity and guide treatment decisions. The nomogram is not reliable in cases of unknown ingestion time, delayed presentation (>24 hours), chronic or staggered overdoses, or extended-release formulations. Additional laboratory studies include AST, ALT, INR, bilirubin, serum glucose, renal function tests, and screening for co-ingestants. Pregnancy testing is required in women of childbearing age.
Management centers on rapid initiation of therapy. Consultation with a Poison Control Center is strongly recommended. Activated charcoal may be administered within 4 hours of ingestion if the patient presents early. The definitive treatment is N-acetylcysteine (NAC), which replenishes glutathione, enhances non-toxic metabolism of acetaminophen, and improves outcomes even when started after liver injury has begun. NAC should be administered whenever toxicity is suspected or cannot be reliably excluded.
NAC may be given intravenously over 21 hours or orally over 72 hours. Intravenous NAC provides predictable absorption and a shorter treatment course but carries a risk of anaphylactoid reactions, whereas oral NAC is effective but commonly causes nausea and vomiting. Therapy should be continued if acetaminophen levels remain detectable, liver enzymes are elevated, or coagulopathy persists. In rare, severe cases with extremely high acetaminophen levels, metabolic acidosis, or altered mental status, hemodialysis may be indicated, with continued NAC administration.
All patients with confirmed acetaminophen poisoning require hospital admission, often to an intensive care unit for close monitoring. When treated promptly, prognosis is excellent, with approximately 90% of patients recovering fully. Acute liver failure is uncommon in young children. Psychiatric evaluation is necessary following intentional ingestions, and patient education on appropriate dosing and awareness of acetaminophen-containing combination products is essential to prevent recurrence.
- Published on
KembaraXtra-Medicine: Acanthosis Nigricans
Acanthosis nigricans (AN) is a dermatologic condition characterized by dark, velvety, thickened skin that appears in a symmetric distribution, most commonly affecting intertriginous areas such as the axillae, neck, and groin. The condition is most often associated with insulin resistance, particularly in the setting of obesity and diabetes mellitus, but it can also occur less commonly due to underlying malignancy, medication effects, or congenital syndromes. AN itself is not dangerous, but it is an important cutaneous marker of systemic disease and warrants further evaluation.
AN is coded under ICD-10-CM L83. The reported prevalence varies widely across studies, but available data suggest that AN is more commonly observed among Black Americans, Native Americans, and Hispanic Americans compared with White or Asian Americans. This condition can affect individuals of all ages. Major risk factors include obesity, insulin resistance, type 2 diabetes, and malignancy, particularly gastrointestinal adenocarcinomas in cases of malignant or paraneoplastic AN.
Clinically, individuals with AN are often asymptomatic, though some may report pruritus or irritation. On examination, the affected skin appears hyperpigmented, thickened, and velvety, initially presenting as dry, rough, gray-brown to black patches. The most commonly involved sites include the axillae, groin, posterior and lateral neck, and popliteal fossae. In more extensive or severe cases, involvement of mucosal surfaces such as the lips, buccal mucosa, conjunctiva, and areolae may be seen. Rapid onset, extensive involvement, or mucosal disease should raise concern for an underlying malignancy.
The pathogenesis of AN is primarily related to hyperinsulinemia, which leads to direct and indirect stimulation of insulin-like growth factor (IGF) receptors on keratinocytes and fibroblasts. This stimulation promotes epidermal proliferation and dermal thickening. Other growth factor pathways, including epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor (FGFR) signaling, may also play contributory roles. Mechanical factors such as friction and perspiration are thought to exacerbate AN, which helps explain its predilection for intertriginous regions. Clinically, AN is often categorized as benign (metabolic-related) or malignant/paraneoplastic, though additional subclassifications exist.
The diagnosis of AN is typically clinical, based on history and physical examination. From a dermatologic standpoint, conditions that may resemble AN include intertriginous granular parakeratosis, confluent and reticulated papillomatosis, Haber syndrome, Dowling–Degos disease, and reticulate acropigmentation of Kitamura. Because AN is frequently a manifestation of systemic disease, evaluation should also consider associated or underlying conditions such as prediabetes, diabetes, obesity, metabolic syndrome, polycystic ovary syndrome (PCOS), nonalcoholic fatty liver disease (NAFLD), chronic glucocorticoid exposure, hypertension, hyperlipidemia, and malignancy.
The workup of AN should be guided by clinical context and focuses on identifying underlying causes. Recommended laboratory tests include fasting blood glucose and hemoglobin A1c to assess for prediabetes or diabetes, fasting lipid panel for hyperlipidemia, and liver function tests to screen for fatty liver disease. In patients with features of hyperandrogenism or menstrual irregularities suggestive of PCOS, serum total testosterone and early morning 17-hydroxyprogesterone may be indicated. Imaging studies are not routinely required but may include transvaginal ultrasound when PCOS is suspected or CT/MRI if there is concern for malignancy based on clinical features such as sudden onset or rapid progression.
Management of AN centers on treating the underlying condition, which is the most effective approach. In cases related to obesity and insulin resistance, weight loss through diet and exercise is the cornerstone of therapy and often leads to gradual improvement or resolution of skin findings. If AN is medication-induced, discontinuation of the offending agent is recommended when feasible. Associated conditions such as diabetes, PCOS, hypertension, hyperlipidemia, or malignancy should be managed according to standard guidelines.
When AN persists despite optimal management of the underlying cause, adjunctive dermatologic treatments may be used for cosmetic or symptomatic relief. These include topical retinoids, vitamin D analogues, keratolytic agents, and, in more refractory cases, systemic retinoids or laser therapy. Referral to endocrinology is often helpful for management of metabolic disorders, and referral to a nutritionist can support sustainable lifestyle changes.
A key clinical pearl is that acanthosis nigricans is a sign, not a diagnosis. Its presence should prompt clinicians to search for and address the underlying disease process. Preventive strategies focus on maintaining healthy lifestyle habits, including balanced nutrition, regular physical activity, and routine primary care follow-up with appropriate metabolic and cancer screening, which can reduce the risk of developing AN and its associated conditions.
- Published on
Acquired Immunodeficiency Syndrome (AIDS)
Acquired immunodeficiency syndrome (AIDS) is the advanced stage of infection caused by the human immunodeficiency virus (HIV). It is characterized by progressive destruction of cell-mediated immunity, particularly CD4⁺ T lymphocytes, which leads to opportunistic infections, malignancies, and systemic complications. A diagnosis of AIDS is made in a person with confirmed HIV infection when the CD4 cell count falls below 200 cells/mm³ (or <14% of total lymphocytes) or when specific aids-defining conditions are present, even if symptoms otherwise minimal.< />pan>
In the United States, approximately 1.2 million people are living with HIV, and a subset have progressed to AIDS. New diagnoses occur disproportionately among Black/African American and Latino/Hispanic populations, and the majority of cases are among men, particularly gay, bisexual, and other men who have sex with men (MSM). The most commonly affected age group is 25 to 59 years. Although there is no proven hereditary predisposition, individuals with certain genetic mutations, such as CCR5 deletions, are less susceptible to HIV infection and may progress more slowly to AIDS. Without treatment, HIV can also be transmitted vertically from mother to fetus or neonate.
Clinical presentation varies widely. Some individuals are asymptomatic, while others present with nonspecific symptoms such as fever, weight loss, anorexia, and fatigue. As immune function declines, patients develop opportunistic infections involving the lungs (e.g., Pneumocystis jirovecii pneumonia, tuberculosis), central nervous system (e.g., toxoplasmosis, cryptococcosis, progressive multifocal leukoencephalopathy), gastrointestinal tract (e.g., chronic cryptosporidiosis, CMV colitis), eyes (e.g., CMV retinitis), and skin. AIDS-related malignancies include Kaposi sarcoma, primary CNS lymphoma, invasive cervical cancer, and high-grade B-cell non-Hodgkin lymphomas.
HIV infection is caused by HIV-1 (most common worldwide) or HIV-2 (less common, mainly in West Africa). Transmission occurs through sexual contact, needle sharing during injection drug use, transfusion of contaminated blood products, and vertical transmission from mother to child during pregnancy, delivery, or breastfeeding.
Diagnosis relies on HIV antibody/antigen testing, followed by assessment of immune and virologic status. Key laboratory studies include CD4 cell count to gauge immunodeficiency and HIV viral load (HIV RNA PCR) to guide therapy and monitor treatment response. Additional evaluation commonly includes screening for sexually transmitted infections, hepatitis A, B, and C, syphilis, toxoplasmosis, and tuberculosis. Imaging studies such as chest radiography or CT and brain MRI or CT are used when pulmonary or neurologic symptoms suggest opportunistic disease.
The cornerstone of management is early and sustained antiretroviral therapy (ART), which should be initiated in all patients with HIV regardless of CD4 count. ART suppresses viral replication, allows immune recovery, reduces opportunistic infections, and dramatically improves survival. Modern regimens typically combine two nucleoside reverse transcriptase inhibitors with an integrase inhibitor, and are generally well tolerated. In addition to ART, patients with AIDS often require prophylactic therapy to prevent infections such as Pneumocystis jirovecii pneumonia and Mycobacterium avium complex until immune reconstitution occurs.
Nonpharmacologic management includes maintaining adequate nutrition, practicing safe sex, avoiding needle sharing, and minimizing exposure to opportunistic pathogens. Vaccinations against influenza, pneumococcus, hepatitis A and B, meningococcus, COVID-19, and Tdap are recommended, while live vaccines are generally avoided in patients with advanced immunosuppression.
The prognosis of HIV/AIDS has changed dramatically. With consistent access to ART and expert medical follow-up, HIV is now a chronic, manageable condition, and many patients enjoy near-normal life expectancy and quality of life. All individuals diagnosed with HIV or AIDS should be referred to clinicians experienced in HIV care to ensure optimal treatment, monitoring, and prevention of complications.
- Published on
KembaraXtra-Medicine- Acromegaly
Acromegaly is a chronic, progressive disorder caused by excess secretion of growth hormone (GH), which in turn stimulates increased production of insulin-like growth factor 1 (IGF-1). The disease develops insidiously, often over many years, and may lead to significant morbidity and mortality if left untreated, particularly from cardiovascular and respiratory complications.
The ICD-10-CM code for acromegaly and pituitary gigantism is E22.0. The incidence is approximately 3 to 4 new cases per 1 million people annually, with a prevalence of 50 to 60 cases per 1 million, and some estimates as high as 90 per 1 million. Acromegaly occurs slightly more often in women. The typical age at diagnosis is around 40 years in men and 45 years in women.
Clinically, patients develop coarse facial features due to progressive soft tissue overgrowth. Common findings include coarse, oily skin, excessive sweating, and macrocephaly. Enlargement of the hands and feet produces broad, spade-like, fleshy extremities, often accompanied by a history of increasing ring, glove, hat, or shoe size. Facial changes such as enlargement of the nose, brow, and jaw, along with prognathism, may result in an underbite.
Musculoskeletal symptoms are common and include muscle weakness, decreased exercise tolerance, arthralgias, severe osteoarthritis, and vertebral fractures. Neurologic and compressive symptoms from the pituitary tumor may include headaches and visual field defects. Carpal tunnel syndrome is frequently seen due to soft tissue swelling.
Acromegaly is also associated with multiple systemic complications. These include diabetes mellitus, hypertension, mild to moderate obesity, and severe obstructive sleep apnea, often related to macroglossia and upper airway soft tissue enlargement. Cardiac involvement is a major contributor to morbidity and mortality and may manifest as cardiomyopathy, left ventricular hypertrophy, valvular heart disease, diastolic dysfunction, and arrhythmias. Patients may also develop benign tumors such as skin tags, uterine fibroids, prostate hypertrophy, and colon polyps, and women may experience menstrual dysfunction.
In most cases, acromegaly results from a pituitary adenoma arising from the anterior pituitary gland. Rarely, it is caused by ectopic secretion of GH or growth hormone–releasing hormone (GHRH) from nonpituitary tumors. Conditions that may mimic or be associated with acromegaly include neuroendocrine tumors, McCune-Albright syndrome, and pachydermoperiostosis.
Diagnosis begins with biochemical testing followed by imaging to localize the source of hormone excess. The initial screening test is a serum IGF-1 level; a normal IGF-1 level makes acromegaly unlikely. If IGF-1 is elevated or equivocal, an oral glucose tolerance test is performed. Failure of GH to suppress to below 1 ng/mL after a glucose load confirms the diagnosis. Random GH measurements are not recommended because of the hormone’s pulsatile secretion.
Once biochemical confirmation is obtained, imaging is used to identify the tumor. MRI of the pituitary and hypothalamus is the preferred modality, while CT scanning is reserved for patients who cannot undergo MRI.
The treatment of choice is transsphenoidal microsurgical removal of the pituitary adenoma. Surgical success depends on tumor size, with failure rates of approximately 10% to 20% for microadenomas and 25% to 50% for macroadenomas confined to the sella. When surgery is contraindicated, incomplete, or when rapid control is needed before surgery (such as in patients with severe sleep apnea or heart failure), medical therapy is indicated.
Medical treatment options include somatostatin receptor ligands (octreotide, lanreotide, pasireotide), which suppress GH secretion and are commonly used preoperatively or postoperatively in patients with residual disease. Pegvisomant, a GH receptor antagonist, is particularly effective for moderate to severe persistent disease or in patients intolerant of somatostatin analogs. Combination therapy with somatostatin analogs and pegvisomant can achieve very high biochemical control rates. Cabergoline, a dopamine agonist, may be used in patients with mild residual disease or as adjunct therapy.
Radiotherapy, including stereotactic radiosurgery (gamma knife), is reserved for patients with persistent or recurrent disease after surgery who do not respond adequately to medical therapy. A major long-term complication of radiotherapy is hypopituitarism, which can occur in up to 50% of patients, necessitating lifelong endocrine follow-up.
If left untreated, acromegaly is associated with an increased mortality rate, mainly due to cardiovascular and respiratory complications. Achieving biochemical control significantly reduces the risk of diabetes and cardiovascular disease. While treatment can reverse many soft tissue and metabolic changes, bone and joint abnormalities are generally irreversible, highlighting the importance of early diagnosis and management.
A key clinical pearl is that GH excess occurring before epiphyseal closure in children and adolescents results in pituitary gigantism, rather than acromegaly. The safety and efficacy of somatostatin receptor ligands and pegvisomant during pregnancy remain uncertain.
- Published on
KembaraXtra-Medicine: Acne Vulgaris
Acne vulgaris is a chronic disorder of the pilosebaceous unit caused by abnormal shedding of follicular epithelium that blocks the follicular canal and promotes inflammation. This process leads to the development of comedones, papules, pustules, nodules/cysts, and, in some patients, scarring and dyspigmentation. Lesions are broadly categorized as noninflammatory (open and closed comedones) and inflammatory (papules, pustules, nodules, and cysts). Inflammatory acne may be described as papulopustular, nodulocystic, or mixed. Although many grading scales exist, there is no universally accepted severity system; clinically, acne is often described as mild, moderate, or severe based on lesion type and burden.
In general, mild acne is dominated by comedones with few inflammatory lesions (often fewer than 10) and no nodules or cysts. Moderate acne involves more numerous inflammatory papules and pustules (often 10–40) along with comedones, and “moderately severe” acne includes higher inflammatory counts or a small number of deeper nodulocystic lesions. Severe acne includes extensive papules and pustules and/or many nodulocystic lesions, often with early scarring. A pattern of deeper lesions along the mandible and anterolateral neck, menstrual flares, and signs of androgen excess such as hirsutism or irregular menses suggests hormonally driven acne.
Acne is commonly referred to simply as acne and is coded under ICD-10-CM L70.0 (acne vulgaris), with additional codes for specific variants such as acne conglobata, infantile/neonatal acne, acne excoriée, and others. Acne is the most common skin disease in the United States and is most prevalent in teenagers, affecting up to 85% to some degree. Incidence peaks between ages 15 and 18 in all genders. While acne often improves before age 25, a substantial minority persists into adulthood, especially in women, with a portion continuing into the mid-40s. Increased “acne mechanica” related to prolonged mask use has also been observed.
Clinical findings include open comedones (blackheads) and closed comedones (whiteheads), inflammatory papules and pustules, deeper nodules or cysts, and occasionally ectatic pores. Many patients develop postinflammatory erythema or hyperpigmentation, and some develop scars such as ice-pick, rolling, boxcar/crateriform, or keloidal scars. Lesions often coexist at different stages of evolution. The typical distribution is the face, upper chest, and back, while hormonal patterns more often involve the jawline and neck.
The underlying pathogenesis centers on comedone formation driven by increased sebum production and abnormal keratinization, which blocks follicles. This environment allows overgrowth of Cutibacterium acnes (formerly Propionibacterium acnes), promoting inflammation. Acne can be worsened by environmental factors such as hot, humid climates; certain medications and exposures (including iodine-containing cough mixtures, pomades/hair greases, anabolic steroids, progestins, lithium, and halogenated hydrocarbons); mechanical friction from sports gear or excessive washing; and stress, which may exacerbate acne via hypothalamic–pituitary–adrenal axis effects and androgen activation.
Diagnosis is clinical, but the differential is broad and includes folliculitis (including gram-negative), perioral dermatitis, rosacea, steroid acne, hidradenitis suppurativa, pseudofolliculitis barbae, keratosis pilaris, seborrheic dermatitis, drug eruptions, and occupational oil/grease exposure. Workup relies on history and physical examination, including prior treatments, skincare products, cosmetic use, family history, medication review (including OTC agents), and in females, the presence of cyclic flares or hormonal features. Clinicians should consider hyperandrogenism in women with hirsutism, irregular menses, or androgenic alopecia, and in children with early-onset acne, seborrhea, or acanthosis nigricans.
Routine laboratory testing is not typically needed. Patients who may be treated with isotretinoin should have baseline liver enzymes and triglycerides checked, and pregnancy testing is required before starting and during therapy due to strong teratogenic risk. If hyperandrogenism is suspected, evaluation may include DHEAS, total/free testosterone, LH, and FSH, though women with regular menses often do not require serum androgen testing.
Treatment is best approached with combination therapy targeting multiple pathogenic pathways. Nonpharmacologic options include selected light-based therapies such as blue light for moderate inflammatory acne, though long-term benefit compared with standard therapy is uncertain. Dietary counseling is appropriate in obese patients, and some evidence suggests high glycemic diets and certain dairy patterns may worsen acne, though the strength of association is debated.
For mild acne, first-line therapy typically includes benzoyl peroxide, a topical retinoid, or combination topical regimens, including topical antibiotics when inflammation is present. Topical therapies require 6 to 8 weeks of consistent use to assess effectiveness. Comedonal acne responds best to topical retinoids (e.g., adapalene, tretinoin, tazarotene), which normalize follicular keratinization and are comedolytic; salicylic acid washes can be helpful as adjuncts. Benzoyl peroxide is often added to reduce bacterial burden and inflammation but may cause irritation and dryness.
For inflammatory acne, topical antibiotics (such as clindamycin or erythromycin) are commonly used with benzoyl peroxide to reduce resistance and improve efficacy, and fixed-dose combination products can simplify regimens. Moderate to severe inflammatory acne may require oral antibiotics (commonly doxycycline or minocycline), ideally limited to 3–6 months to reduce resistance and microbiome disruption. Patients with nodulocystic acne or moderate-to-severe acne unresponsive to standard therapy may need systemic options such as isotretinoin, hormonal therapy (combined oral contraceptives), and/or antiandrogen therapy such as spironolactone; intralesional corticosteroid injections can rapidly improve large nodules.
Referral to dermatology is appropriate for severe, scarring, refractory acne or when procedures are needed, including intralesional injections, comedone extraction, and treatments for scarring such as resurfacing lasers, dermabrasion, chemical peels, or other scar-directed interventions. Important clinical pearls include recognizing that acne may worsen during the first few weeks of retinoid therapy before improving, and that worsening inflammatory acne after prolonged antibiotic use should raise suspicion for gram-negative folliculitis. Patients should be counseled that acne is usually controllable but not quickly “cured,” and meaningful improvement generally requires at least 4–8 weeks of consistent therapy, with attention to adherence and gentle skin care to minimize irritation and scarring.
- Published on
KembaraXtra-Medicine- Acromioclavicular Dislocation
The acromioclavicular (AC) joint is formed by the articulation between the distal clavicle and the acromion and is located on the anterosuperior aspect of the shoulder. This joint is stabilized primarily by the acromioclavicular (AC) ligaments and the coracoclavicular (CC) ligaments. An acromioclavicular dislocation, also referred to as an AC joint separation, occurs when trauma disrupts these stabilizing structures. The severity of injury can range from a mild ligament sprain to complete rupture of the AC and CC ligaments, with the degree of damage correlating directly with the amount of force applied to the shoulder.
AC joint dislocations most commonly result from direct trauma to the shoulder, such as a blow that drives the acromion inferiorly relative to the clavicle. These injuries are frequently seen in contact sports like football, rugby, lacrosse, and ice hockey, as well as in high-impact motor vehicle accidents. Falls, including falls onto an outstretched hand, can also produce AC joint injuries, though high-energy mechanisms are more likely to result in severe dislocations.
The incidence of AC joint dislocations in the general population ranges from 0.8 to 4.6 per 10,000 people per year, accounting for approximately 10% of shoulder girdle injuries in urban populations. Peak incidence occurs in individuals aged 29 to 40 years, and these injuries are most commonly seen in patients younger than 40 years. Males are more frequently affected than females. No genetic predisposition has been identified.
Clinically, patients typically present with anterior-superior shoulder pain following trauma. Physical examination may reveal visible deformity when compared with the contralateral shoulder, particularly in higher-grade injuries. A classic finding is the “piano key sign,” in which the distal clavicle appears elevated and rebounds when downward pressure is applied. Patients may also have localized tenderness, swelling, and limited shoulder motion. It is essential to assess neurovascular status, evaluate clavicular mobility, and examine surrounding joints and soft tissues for associated injuries.
Diagnosis is often made based on clinical presentation and plain radiographs. Standard imaging includes bilateral anteroposterior views of the AC joints, axillary lateral views, Zanca views, and cross-body adduction views. Upright imaging is preferred, as supine films may underestimate injury severity. The degree of displacement is classified using the Rockwood classification, which categorizes injuries from Type I (ligament sprain) to Type VI (severe inferior displacement of the clavicle). This classification system guides treatment decisions.
Management of AC joint dislocations depends largely on injury severity. Type I and Type II injuries are treated nonoperatively with rest, ice, NSAIDs, sling immobilization, activity modification, and physical therapy. Type III injuries remain controversial; many patients achieve good outcomes with conservative management, though orthopedic consultation is recommended. Surgical intervention may be considered in patients with persistent symptoms despite nonoperative treatment. Type IV, V, and VI injuries typically require surgical management and should be referred promptly to an orthopedic surgeon.
Nonoperative treatment focuses on pain control, immobilization, and gradual rehabilitation to restore range of motion and strength. Operative treatment usually involves open reduction with reconstruction of the coracoclavicular ligaments and repair of the deltotrapezial fascia. There is no single superior surgical technique, and outcomes are generally comparable across methods. Chronic injuries may be managed either conservatively or surgically depending on symptoms and functional impairment.
Most patients managed nonoperatively recover well, regaining near-normal function by 6 weeks and returning to full activity by approximately 12 weeks. Surgical cases require a longer recovery period, often involving 6 weeks of immobilization and return to full activity by 6 months. While many patients are left with a visible deformity at the AC joint, it is often cosmetic and asymptomatic.
Preventive strategies include the use of proper shoulder protective padding in contact sports and education on safe falling techniques in activities with a high risk of falls. Patients and families should be counseled on both nonoperative and operative treatment options, expected recovery timelines, and the possibility of persistent but painless deformity following healing.
- Published on
KembaraXtra-Medicine- Actinomycosis
Actinomycosis is an indolent, slowly progressive bacterial infection caused by anaerobic or microaerophilic organisms of the genus Actinomyces. These bacteria normally colonize the mouth, gastrointestinal tract, and female genital tract and do not exist freely in the environment. Disease occurs only when there is disruption of normal mucosal barriers, allowing organisms to invade deeper tissues. Actinomycosis is characterized by painful abscess formation, dense soft tissue infiltration, and the development of draining sinus tracts.
Actinomycosis occurs worldwide but has become relatively rare, with an estimated incidence far lower than the historical rate of approximately 1 in 300,000 reported in the 1970s. Improved oral hygiene and widespread antibiotic use have contributed to this decline. Males are affected more frequently than females, with a ratio of approximately 3:1, and the disease can occur at any age, though it is most commonly seen in middle-aged adults.
Clinically, actinomycosis can involve almost any organ system, most often following local tissue injury or mucosal breach. The most common form is cervicofacial actinomycosis, accounting for about 60% of cases. This form typically arises in the setting of poor dental hygiene, recent dental procedures, or minor oral trauma. Patients may present with painful soft tissue swelling near the angle of the mandible, fever, weight loss, trismus, and draining sinus tracts or fistulas.
Thoracic actinomycosis usually results from aspiration of oral secretions containing Actinomyces species, particularly in patients with poor oral hygiene. Symptoms include fever, cough, weight loss, and pleuritic chest pain. The infection may extend beyond the lungs to involve the pleura, mediastinum, or chest wall, leading to complications such as empyema, pericarditis, chest wall sinus tracts, or tracheoesophageal fistulas.
Abdominal actinomycosis commonly follows gastrointestinal surgery, appendicitis, bowel perforation, or diverticulitis. It most often affects the ileocecal region and presents with abdominal pain, fever, weight loss, and sometimes a palpable mass. Extension to adjacent organs such as the liver can result in abscess formation and jaundice, and sinus tracts may extend to the abdominal wall. Pelvic actinomycosis may occur by contiguous spread, particularly in women, and has been associated with intrauterine device (IUD) use.
Actinomycosis is most frequently caused by Actinomyces israelii, though other species such as A. naeslundii, A. odontolyticus, A. viscosus, and A. meyeri may be involved. These organisms are gram-positive, filamentous, non–spore-forming rods. Infections are typically polymicrobial, often involving organisms such as Streptococcus, Eikenella corrodens, Bacteroides, Enterococcus, and Fusobacterium species. Predisposing factors include diabetes mellitus, malnutrition, immunosuppression, and chronic mucosal injury.
Diagnosis relies on isolating Actinomyces organisms in the appropriate clinical context. Specimens are obtained through abscess aspiration, sinus tract excision, or tissue biopsy and must be cultured under anaerobic conditions for at least 5 to 7 days, as growth is slow. A characteristic diagnostic feature is the presence of sulfur granules in pus or tissue specimens. These yellow granules represent dense colonies of Actinomyces and are diagnostic when identified microscopically, although they may take weeks to grow in culture.
Imaging studies are useful adjuncts to define the extent of disease and localize infection. Chest radiography and computed tomography (CT) scans of the head, chest, abdomen, or pelvis are commonly used depending on the suspected site of involvement. Imaging often reveals infiltrative masses that cross tissue planes, a hallmark of actinomycosis.
Treatment of actinomycosis requires prolonged antibiotic therapy and, in many cases, surgical intervention. Nonpharmacologic management includes incision and drainage of abscesses and excision of sinus tracts when indicated. Penicillin remains the treatment of choice. Initial therapy typically consists of intravenous penicillin or ampicillin for 4 to 6 weeks, followed by prolonged oral therapy with penicillin V for an additional 4 to 6 weeks or longer. In complicated cases, total treatment duration may extend to 6 to 12 months. For penicillin-allergic patients, alternatives include doxycycline, erythromycin, or clindamycin.
With appropriate treatment, the prognosis of actinomycosis is excellent. Untreated disease, however, may spread extensively to contiguous tissues while ignoring normal anatomic boundaries. Hematogenous spread is rare. Because relapse can occur if therapy is too short, long-term antibiotic treatment is essential. Referral to an infectious disease specialist is recommended when actinomycosis is suspected, and surgical consultation is often necessary for management of abscesses, sinus tracts, or necrotic tissue.
Important clinical considerations include the absence of person-to-person transmission and the fact that isolation of Actinomyces in an asymptomatic individual does not indicate disease. Pelvic actinomycosis should be considered in women with long-term IUD use, and central nervous system involvement, though uncommon, can occur in the form of brain abscesses.
Actinomycosis is an indolent, slowly progressive bacterial infection caused by anaerobic or microaerophilic organisms of the genus Actinomyces. These bacteria normally colonize the mouth, gastrointestinal tract, and female genital tract and do not exist freely in the environment. Disease occurs only when there is disruption of normal mucosal barriers, allowing organisms to invade deeper tissues. Actinomycosis is characterized by painful abscess formation, dense soft tissue infiltration, and the development of draining sinus tracts.
Actinomycosis occurs worldwide but has become relatively rare, with an estimated incidence far lower than the historical rate of approximately 1 in 300,000 reported in the 1970s. Improved oral hygiene and widespread antibiotic use have contributed to this decline. Males are affected more frequently than females, with a ratio of approximately 3:1, and the disease can occur at any age, though it is most commonly seen in middle-aged adults.
Clinically, actinomycosis can involve almost any organ system, most often following local tissue injury or mucosal breach. The most common form is cervicofacial actinomycosis, accounting for about 60% of cases. This form typically arises in the setting of poor dental hygiene, recent dental procedures, or minor oral trauma. Patients may present with painful soft tissue swelling near the angle of the mandible, fever, weight loss, trismus, and draining sinus tracts or fistulas.
Thoracic actinomycosis usually results from aspiration of oral secretions containing Actinomyces species, particularly in patients with poor oral hygiene. Symptoms include fever, cough, weight loss, and pleuritic chest pain. The infection may extend beyond the lungs to involve the pleura, mediastinum, or chest wall, leading to complications such as empyema, pericarditis, chest wall sinus tracts, or tracheoesophageal fistulas.
Abdominal actinomycosis commonly follows gastrointestinal surgery, appendicitis, bowel perforation, or diverticulitis. It most often affects the ileocecal region and presents with abdominal pain, fever, weight loss, and sometimes a palpable mass. Extension to adjacent organs such as the liver can result in abscess formation and jaundice, and sinus tracts may extend to the abdominal wall. Pelvic actinomycosis may occur by contiguous spread, particularly in women, and has been associated with intrauterine device (IUD) use.
Actinomycosis is most frequently caused by Actinomyces israelii, though other species such as A. naeslundii, A. odontolyticus, A. viscosus, and A. meyeri may be involved. These organisms are gram-positive, filamentous, non–spore-forming rods. Infections are typically polymicrobial, often involving organisms such as Streptococcus, Eikenella corrodens, Bacteroides, Enterococcus, and Fusobacterium species. Predisposing factors include diabetes mellitus, malnutrition, immunosuppression, and chronic mucosal injury.
Diagnosis relies on isolating Actinomyces organisms in the appropriate clinical context. Specimens are obtained through abscess aspiration, sinus tract excision, or tissue biopsy and must be cultured under anaerobic conditions for at least 5 to 7 days, as growth is slow. A characteristic diagnostic feature is the presence of sulfur granules in pus or tissue specimens. These yellow granules represent dense colonies of Actinomyces and are diagnostic when identified microscopically, although they may take weeks to grow in culture.
Imaging studies are useful adjuncts to define the extent of disease and localize infection. Chest radiography and computed tomography (CT) scans of the head, chest, abdomen, or pelvis are commonly used depending on the suspected site of involvement. Imaging often reveals infiltrative masses that cross tissue planes, a hallmark of actinomycosis.
Treatment of actinomycosis requires prolonged antibiotic therapy and, in many cases, surgical intervention. Nonpharmacologic management includes incision and drainage of abscesses and excision of sinus tracts when indicated. Penicillin remains the treatment of choice. Initial therapy typically consists of intravenous penicillin or ampicillin for 4 to 6 weeks, followed by prolonged oral therapy with penicillin V for an additional 4 to 6 weeks or longer. In complicated cases, total treatment duration may extend to 6 to 12 months. For penicillin-allergic patients, alternatives include doxycycline, erythromycin, or clindamycin.
With appropriate treatment, the prognosis of actinomycosis is excellent. Untreated disease, however, may spread extensively to contiguous tissues while ignoring normal anatomic boundaries. Hematogenous spread is rare. Because relapse can occur if therapy is too short, long-term antibiotic treatment is essential. Referral to an infectious disease specialist is recommended when actinomycosis is suspected, and surgical consultation is often necessary for management of abscesses, sinus tracts, or necrotic tissue.
Important clinical considerations include the absence of person-to-person transmission and the fact that isolation of Actinomyces in an asymptomatic individual does not indicate disease. Pelvic actinomycosis should be considered in women with long-term IUD use, and central nervous system involvement, though uncommon, can occur in the form of brain abscesses.
- Published on
KembaraXtra-Medicine- Actinic Keratosis
Actinic keratoses (AKs) are common premalignant skin lesions that typically present as multiple, ill-defined pink to yellow-brown, dry, scaly patches or plaques. They occur predominantly on chronically sun-exposed areas and are most often seen in middle-aged and elderly individuals. AKs are also known as solar keratoses or senile keratoses and are classified under ICD-10-CM code L57.0.
AKs are highly prevalent worldwide, with frequency varying by geographic location and sun exposure. In the northern hemisphere, approximately 11% to 25% of adults have at least one AK, whereas in regions closer to the equator, prevalence rises to 40% to 60%. In the United States, tens of millions of cases are estimated annually. The condition is more common in fair-skinned individuals, particularly those who burn rather than tan, and prevalence increases significantly with age. Men are affected more often than women, especially between the ages of 65 and 74 years.
Clinically, AKs appear on sun-damaged skin, most commonly involving the face, neck, scalp, ears, dorsal hands, and forearms. Early lesions may present as subtle erythematous patches with minimal scaling, while more advanced lesions develop thicker, yellowish, hyperkeratotic scales and feel rough or gritty on palpation. Lesions are usually less than 1 cm in diameter. Surrounding skin often shows signs of chronic photodamage, including atrophy, pigmentary changes, and telangiectasia. Several clinical variants exist, such as hypertrophic AKs with cutaneous horns, lichenoid AKs, proliferative AKs, pigmented AKs, and actinic cheilitis involving the lips.
The primary etiologic factor in the development of AKs is chronic ultraviolet (UV) radiation exposure. Additional contributing factors include ionizing radiation, arsenic exposure, polycyclic hydrocarbons, immunosuppression, human papillomavirus infection, cigarette smoke, and chronic skin injury. Genetic susceptibility also plays a role, particularly in conditions such as xeroderma pigmentosum and other inherited disorders associated with impaired DNA repair or increased skin cancer risk. Mutations in the p53 tumor suppressor gene are commonly implicated.
Diagnosis of actinic keratosis is usually clinical, based on characteristic appearance and patient history of sun exposure. A biopsy is not routinely required but should be performed when lesions exhibit concerning features such as tenderness, bleeding, ulceration, rapid growth, marked hyperkeratosis, or failure to respond to standard treatment. Histopathology typically reveals atypical keratinocytes in the basal layers of the epidermis, with disordered maturation and parakeratosis.
Treatment depends on the number, size, location, and thickness of lesions. Isolated lesions are commonly treated with cryotherapy using liquid nitrogen. For patients with multiple lesions or field cancerization, topical therapies such as 5-fluorouracil, imiquimod, diclofenac gel, tirbanibulin ointment, or photodynamic therapy may be used. Procedural options include curettage, excision, chemical peels, dermabrasion, and laser therapy. Combination and sequential treatment approaches are frequently employed, particularly in refractory or extensive disease.
Referral to a dermatologist is recommended for patients with suspicious or recurrent lesions, extensive disease, immunosuppression, or when biopsy is indicated. Long-term follow-up is essential, typically on an annual or semiannual basis, due to the risk of progression to squamous cell carcinoma. Although the risk of transformation of an individual AK is low, the cumulative risk increases in patients with multiple lesions.
Prevention is a critical component of management. Measures include avoidance of excessive sun exposure, regular use of broad-spectrum sunscreens, protective clothing, and avoidance of tanning beds. Routine self-examination and regular professional skin evaluations are advised, especially for high-risk individuals. Preventive strategies such as nicotinamide supplementation and consistent sunscreen use have been shown to reduce the development of new actinic keratoses.
Actinic keratoses (AKs) are common premalignant skin lesions that typically present as multiple, ill-defined pink to yellow-brown, dry, scaly patches or plaques. They occur predominantly on chronically sun-exposed areas and are most often seen in middle-aged and elderly individuals. AKs are also known as solar keratoses or senile keratoses and are classified under ICD-10-CM code L57.0.
AKs are highly prevalent worldwide, with frequency varying by geographic location and sun exposure. In the northern hemisphere, approximately 11% to 25% of adults have at least one AK, whereas in regions closer to the equator, prevalence rises to 40% to 60%. In the United States, tens of millions of cases are estimated annually. The condition is more common in fair-skinned individuals, particularly those who burn rather than tan, and prevalence increases significantly with age. Men are affected more often than women, especially between the ages of 65 and 74 years.
Clinically, AKs appear on sun-damaged skin, most commonly involving the face, neck, scalp, ears, dorsal hands, and forearms. Early lesions may present as subtle erythematous patches with minimal scaling, while more advanced lesions develop thicker, yellowish, hyperkeratotic scales and feel rough or gritty on palpation. Lesions are usually less than 1 cm in diameter. Surrounding skin often shows signs of chronic photodamage, including atrophy, pigmentary changes, and telangiectasia. Several clinical variants exist, such as hypertrophic AKs with cutaneous horns, lichenoid AKs, proliferative AKs, pigmented AKs, and actinic cheilitis involving the lips.
The primary etiologic factor in the development of AKs is chronic ultraviolet (UV) radiation exposure. Additional contributing factors include ionizing radiation, arsenic exposure, polycyclic hydrocarbons, immunosuppression, human papillomavirus infection, cigarette smoke, and chronic skin injury. Genetic susceptibility also plays a role, particularly in conditions such as xeroderma pigmentosum and other inherited disorders associated with impaired DNA repair or increased skin cancer risk. Mutations in the p53 tumor suppressor gene are commonly implicated.
Diagnosis of actinic keratosis is usually clinical, based on characteristic appearance and patient history of sun exposure. A biopsy is not routinely required but should be performed when lesions exhibit concerning features such as tenderness, bleeding, ulceration, rapid growth, marked hyperkeratosis, or failure to respond to standard treatment. Histopathology typically reveals atypical keratinocytes in the basal layers of the epidermis, with disordered maturation and parakeratosis.
Treatment depends on the number, size, location, and thickness of lesions. Isolated lesions are commonly treated with cryotherapy using liquid nitrogen. For patients with multiple lesions or field cancerization, topical therapies such as 5-fluorouracil, imiquimod, diclofenac gel, tirbanibulin ointment, or photodynamic therapy may be used. Procedural options include curettage, excision, chemical peels, dermabrasion, and laser therapy. Combination and sequential treatment approaches are frequently employed, particularly in refractory or extensive disease.
Referral to a dermatologist is recommended for patients with suspicious or recurrent lesions, extensive disease, immunosuppression, or when biopsy is indicated. Long-term follow-up is essential, typically on an annual or semiannual basis, due to the risk of progression to squamous cell carcinoma. Although the risk of transformation of an individual AK is low, the cumulative risk increases in patients with multiple lesions.
Prevention is a critical component of management. Measures include avoidance of excessive sun exposure, regular use of broad-spectrum sunscreens, protective clothing, and avoidance of tanning beds. Routine self-examination and regular professional skin evaluations are advised, especially for high-risk individuals. Preventive strategies such as nicotinamide supplementation and consistent sunscreen use have been shown to reduce the development of new actinic keratoses.
- Published on
KembaraXtra-Medicine- Acute Bronchitis
Acute bronchitis is a self-limited inflammatory condition of the trachea and bronchi, most commonly referred to as a “chest cold.” It is characterized by transient inflammation of the lower airways and typically follows an upper respiratory tract infection. The condition usually resolves on its own without long-term sequelae.
Acute bronchitis is common, particularly during the winter months, and occurs most frequently in smokers, older adults, and young children. In the United States, cough accounts for nearly 30 million ambulatory visits each year, with more than 12 million resulting in a diagnosis of bronchitis. Acute lower respiratory tract infection remains the most common condition treated in primary care settings.
Clinically, acute bronchitis often begins with symptoms typical of a common cold, such as nasal congestion and sore throat, followed by the development of cough. The cough is usually worse in the morning and may be productive, largely due to transient bronchial hyperresponsiveness. Patients may also experience low-grade fever, substernal discomfort that worsens with coughing, postnasal drip, and pharyngeal erythema. On auscultation, rhonchi that clear with coughing and occasional wheezing may be present. Illness severity varies depending on host factors such as age, immune status, smoking history, and underlying medical conditions. While mild cases resolve within 7 to 10 days, cough may persist for up to 3 weeks or longer in some individuals.
The most common cause of acute bronchitis is viral infection. Frequently implicated viruses include rhinovirus, influenza virus, adenovirus, respiratory syncytial virus, parainfluenza virus, coronavirus, and human metapneumovirus. Less commonly, atypical organisms such as Mycoplasma pneumoniae and Chlamydia pneumoniae may be responsible. Bacterial causes are uncommon but include Bordetella pertussis, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
The diagnosis of acute bronchitis is primarily clinical. Important conditions to consider in the differential diagnosis include pneumonia, asthma, sinusitis, bronchiolitis, influenza, gastroesophageal reflux disease, congestive heart failure (particularly in older adults), medication-induced cough, and bronchogenic neoplasm. Diagnostic testing is seldom necessary unless there is concern for pneumonia, influenza, or another serious underlying condition.
Routine laboratory testing is generally not required. Chest radiography is reserved for patients with suspected pneumonia, those with chronic obstructive pulmonary disease who fail to improve, or individuals with concerning features such as high fever, hypoxia, or focal lung findings.
Management of acute bronchitis is largely supportive. Nonpharmacologic measures include avoidance of tobacco smoke and other pulmonary irritants, increased fluid intake, and the use of vaporizers or humidifiers to improve airway comfort. Treatment focuses on symptom relief rather than eradication of infection.
Pharmacologic therapy is aimed at controlling cough and wheezing. Inhaled bronchodilators such as albuterol may be used for 1 to 2 weeks in patients with wheezing or significant cough and have been shown to reduce cough duration in adults with uncomplicated disease. Cough suppressants such as dextromethorphan and expectorants like guaifenesin are commonly recommended. Codeine may be considered for severe cough that significantly disrupts sleep.
Antibiotics are generally not indicated for acute bronchitis and should be reserved for select cases, such as patients with suspected pertussis, confirmed atypical bacterial infection, or those with COPD exacerbations accompanied by increased dyspnea and purulent sputum. Despite evidence showing minimal benefit, antibiotics are prescribed in 70% to 90% of visits for acute bronchitis, contributing to antibiotic resistance and increased adverse effects, particularly gastrointestinal symptoms. Clinical trials have consistently demonstrated no meaningful difference in outcomes between antibiotic and placebo therapy in uncomplicated cases.
The prognosis for acute bronchitis is excellent. Most patients recover fully within 7 to 10 days, though cough commonly persists for 10 to 14 days after presentation. Patients should be reassured about the expected course of illness and advised to seek further evaluation if symptoms worsen or fail to improve.
Referral for pulmonary function testing is generally unnecessary and should be considered only in patients with recurrent episodes of bronchitis or suspected underlying chronic pulmonary disease. Patient education is essential, emphasizing that acute bronchitis is usually viral, antibiotics are unlikely to help, and symptomatic management is the cornerstone of care.
Acute bronchitis is a self-limited inflammatory condition of the trachea and bronchi, most commonly referred to as a “chest cold.” It is characterized by transient inflammation of the lower airways and typically follows an upper respiratory tract infection. The condition usually resolves on its own without long-term sequelae.
Acute bronchitis is common, particularly during the winter months, and occurs most frequently in smokers, older adults, and young children. In the United States, cough accounts for nearly 30 million ambulatory visits each year, with more than 12 million resulting in a diagnosis of bronchitis. Acute lower respiratory tract infection remains the most common condition treated in primary care settings.
Clinically, acute bronchitis often begins with symptoms typical of a common cold, such as nasal congestion and sore throat, followed by the development of cough. The cough is usually worse in the morning and may be productive, largely due to transient bronchial hyperresponsiveness. Patients may also experience low-grade fever, substernal discomfort that worsens with coughing, postnasal drip, and pharyngeal erythema. On auscultation, rhonchi that clear with coughing and occasional wheezing may be present. Illness severity varies depending on host factors such as age, immune status, smoking history, and underlying medical conditions. While mild cases resolve within 7 to 10 days, cough may persist for up to 3 weeks or longer in some individuals.
The most common cause of acute bronchitis is viral infection. Frequently implicated viruses include rhinovirus, influenza virus, adenovirus, respiratory syncytial virus, parainfluenza virus, coronavirus, and human metapneumovirus. Less commonly, atypical organisms such as Mycoplasma pneumoniae and Chlamydia pneumoniae may be responsible. Bacterial causes are uncommon but include Bordetella pertussis, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
The diagnosis of acute bronchitis is primarily clinical. Important conditions to consider in the differential diagnosis include pneumonia, asthma, sinusitis, bronchiolitis, influenza, gastroesophageal reflux disease, congestive heart failure (particularly in older adults), medication-induced cough, and bronchogenic neoplasm. Diagnostic testing is seldom necessary unless there is concern for pneumonia, influenza, or another serious underlying condition.
Routine laboratory testing is generally not required. Chest radiography is reserved for patients with suspected pneumonia, those with chronic obstructive pulmonary disease who fail to improve, or individuals with concerning features such as high fever, hypoxia, or focal lung findings.
Management of acute bronchitis is largely supportive. Nonpharmacologic measures include avoidance of tobacco smoke and other pulmonary irritants, increased fluid intake, and the use of vaporizers or humidifiers to improve airway comfort. Treatment focuses on symptom relief rather than eradication of infection.
Pharmacologic therapy is aimed at controlling cough and wheezing. Inhaled bronchodilators such as albuterol may be used for 1 to 2 weeks in patients with wheezing or significant cough and have been shown to reduce cough duration in adults with uncomplicated disease. Cough suppressants such as dextromethorphan and expectorants like guaifenesin are commonly recommended. Codeine may be considered for severe cough that significantly disrupts sleep.
Antibiotics are generally not indicated for acute bronchitis and should be reserved for select cases, such as patients with suspected pertussis, confirmed atypical bacterial infection, or those with COPD exacerbations accompanied by increased dyspnea and purulent sputum. Despite evidence showing minimal benefit, antibiotics are prescribed in 70% to 90% of visits for acute bronchitis, contributing to antibiotic resistance and increased adverse effects, particularly gastrointestinal symptoms. Clinical trials have consistently demonstrated no meaningful difference in outcomes between antibiotic and placebo therapy in uncomplicated cases.
The prognosis for acute bronchitis is excellent. Most patients recover fully within 7 to 10 days, though cough commonly persists for 10 to 14 days after presentation. Patients should be reassured about the expected course of illness and advised to seek further evaluation if symptoms worsen or fail to improve.
Referral for pulmonary function testing is generally unnecessary and should be considered only in patients with recurrent episodes of bronchitis or suspected underlying chronic pulmonary disease. Patient education is essential, emphasizing that acute bronchitis is usually viral, antibiotics are unlikely to help, and symptomatic management is the cornerstone of care.
